時富投資 01049.HK 深 滬
已收盤 01-09 16:10:00
1.100
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 26股
- 最 低 --
- 昨 收 1.100
- 總市值 8876.80万
- 52周最高 1.710
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.101
- 委 比 15.07%
- 總股本 8069.82万
- 歷史最高 1.140
- 量 比 0.00
- 振 幅 0.00%
- 歷史最低 0.101
- 每 手 2000
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多时富投资（01049.HK）12月31日收盘平盘
证券之星消息，截至2025年12月31日收盘，时富投资(01049.HK)报收于1.06港元，与上一交易日持平，成交量24.0股，成交额22.0港元。
2025-12-31 18:51
董事长关百豪增持时富投资(01049)1.8万股 每股作价1.03港元
香港联交所最新资料显示，12月10日，董事长关百豪增持时富投资(01049)1.8万股，每股作价1.03港元，总金额约为1.85万港元。
2025-12-11 18:53
时富投资（01049.HK）11月27日收盘平盘
证券之星消息，截至2025年11月27日收盘，时富投资(01049.HK)报收于0.78港元，与上一交易日持平，成交量5.0股，成交额4.0港元。
2025-11-27 18:58
时富投资(01049.HK)拟续租香港九龙物业做办公室用途
时富投资(01049.HK)发布公告，于2025年10月22日，财丰有限公司(本公司的全资附属公司)作为租户与代理万泰拓展(作为业主的代理)(独立第三方)订立有关续租该等物业(九龙九龙湾宏泰道23号Manhattan Place 28楼全层)作为本集团办公室用途的要约的续租要约书。
2025-10-22 16:56
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
Celcuity Inc. announced positive Phase 3 results for gedatolisib in treating HR+/HER2-/PIK3CA wild-type advanced breast cancer. The gedatolisib triplet and doublet demonstrated significant improvements in median progression-free survival (PFS) compared to fulvestrant, with reductions in disease progression or death risk by 76% and 67%, respectively. The safety profile was favorable, with low-grade treatment-related adverse events (TRAEs) and low ...
2025-10-18 08:30
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
Celcuity Inc. announced the full enrollment of the PIK3CA mutant cohort in their Phase 3 VIKTORIA-1 clinical trial and provided updated analysis from a Phase 1b trial. The Phase 1b trial showed a median progression-free survival (PFS) of 14.6 months for HR+/HER2-/PIK3CA-mutated advanced breast cancer patients treated with gedatolisib, fulvestrant, and palbociclib. The Phase 3 trial expects to report topline data in late Q1 or early Q2 2026.
2025-10-18 08:30
Cellebrite to Report Third-Quarter 2025 Financial Results on November 12, 2025
<p>Cellebrite (NASDAQ: CLBT), a leader in digital investigative solutions, announced it will release its third-quarter 2025 financial results after the U.S. market close on November 12, 2025. Later that day, the company will host a conference call and webcast at 5:00 p.m. ET to discuss the results and provide a full-year 2025 outlook. Details include a call-in number (203-518-9814 / 800-274-8461) with conference ID CLBTQ325, and webcast links ava...
2025-10-17 13:00
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
Cellectis reported promising Phase 1 data for lasme-cel (UCART22) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The study showed an overall response rate (ORR) of 68% with Process 2 (n=22), 83% at the recommended Phase 2 dose (RP2D, n=12), and 100% in the target Phase 2 population (n=9). Safety was generally well-tolerated with manageable adverse events. In the Phase 2 population, 56% achieved complete remission (CR)/CR ...
2025-10-16 19:19
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
<b>Event Summary:</b> Cellectis is hosting an R&D Day in New York City to present full Phase 1 data and discuss the pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL. <br><br> <b>Event Details:</b> October 16, 2025, 08:30 – 10:30 a.m. ET, in-person and live webcast available. <br> <br> <b>Cellectis Overview:</b> A clinical-stage biotech company developing allogeneic CAR T immunotherapies and gene therapies. <br><br> <b>Webcast:</b> Jo...
2025-10-16 11:00
